These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

414 related items for PubMed ID: 22955035

  • 21. Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies.
    Kerwin E, Ferguson GT, Sanjar S, Goodin T, Yadao A, Fogel R, Maitra S, Sen B, Ayers T, Banerji D.
    Lung; 2017 Dec; 195(6):739-747. PubMed ID: 28993871
    [Abstract] [Full Text] [Related]

  • 22. The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.
    Kato M, Tomii K, Hashimoto K, Nezu Y, Ishii T, Jones CE, Kilbride S, Gross AS, Clifton CS, Lipson DA.
    Int J Chron Obstruct Pulmon Dis; 2019 Dec; 14():2849-2861. PubMed ID: 31839705
    [Abstract] [Full Text] [Related]

  • 23. Effects of moderate hepatic impairment on the pharmacokinetic properties and tolerability of umeclidinium and vilanterol in inhalational umeclidinium monotherapy and umeclidinium/vilanterol combination therapy: an open-label, nonrandomized study.
    Mehta R, Hardes K, Kelleher D, Preece A, Tombs L, Brealey N.
    Clin Ther; 2014 Jul 01; 36(7):1016-1027.e2. PubMed ID: 24947493
    [Abstract] [Full Text] [Related]

  • 24. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects.
    Feldman GJ, Edin A.
    Ther Adv Respir Dis; 2013 Dec 01; 7(6):311-9. PubMed ID: 24004659
    [Abstract] [Full Text] [Related]

  • 25. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
    Dransfield MT, Feldman G, Korenblat P, LaForce CF, Locantore N, Pistolesi M, Watkins ML, Crim C, Martinez FJ.
    Respir Med; 2014 Aug 01; 108(8):1171-9. PubMed ID: 24998880
    [Abstract] [Full Text] [Related]

  • 26. The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial.
    Hanania NA, Feldman G, Zachgo W, Shim JJ, Crim C, Sanford L, Lettis S, Barnhart F, Haumann B.
    Chest; 2012 Jul 01; 142(1):119-127. PubMed ID: 22241764
    [Abstract] [Full Text] [Related]

  • 27. Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials.
    Maltais F, Singh S, Donald AC, Crater G, Church A, Goh AH, Riley JH.
    Ther Adv Respir Dis; 2014 Dec 01; 8(6):169-81. PubMed ID: 25452426
    [Abstract] [Full Text] [Related]

  • 28. Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.
    Feldman GJ, Sousa AR, Lipson DA, Tombs L, Barnes N, Riley JH, Patel S, Naya I, Compton C, Alcázar Navarrete B.
    Adv Ther; 2017 Nov 01; 34(11):2518-2533. PubMed ID: 29094315
    [Abstract] [Full Text] [Related]

  • 29. Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials.
    Ray R, Tombs L, Naya I, Compton C, Lipson DA, Boucot I.
    Pulm Pharmacol Ther; 2019 Aug 01; 57():101802. PubMed ID: 31096036
    [Abstract] [Full Text] [Related]

  • 30. Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol.
    Moretz C, Bengtson LG, Sharpsten L, Koep E, Le L, Tong J, Stanford RH, Hahn B, Ray R.
    Int J Chron Obstruct Pulmon Dis; 2019 Aug 01; 14():2047-2060. PubMed ID: 31564852
    [Abstract] [Full Text] [Related]

  • 31. Genetic effects on treatment response of umeclidinium/vilanterol in chronic obstructive pulmonary disease.
    Condreay L, Huang L, Harris E, Brooks J, Riley JH, Church A, Ghosh S.
    Respir Med; 2016 May 01; 114():123-6. PubMed ID: 27109822
    [Abstract] [Full Text] [Related]

  • 32. Umeclidinium plus vilanterol versus fluticasone propionate plus salmeterol for chronic obstructive pulmonary disease: a meta-analysis of randomized, controlled trials.
    Zhai C, Wang F, Xu R, Sun X, Ma W, Wang L.
    Postgrad Med J; 2024 Sep 22; 100(1188):721-729. PubMed ID: 38652265
    [Abstract] [Full Text] [Related]

  • 33. Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT.
    Marín JM, Mateos L, Roldán J, Echave-Sustaeta JM, Pascual-Guardia S, Pardo MV, Velasco B, Jones CE, Kilbride S, Lipson DA.
    Ther Adv Respir Dis; 2020 Sep 22; 14():1753466620963021. PubMed ID: 33121372
    [No Abstract] [Full Text] [Related]

  • 34. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
    Siler TM, Nagai A, Scott-Wilson CA, Midwinter DA, Crim C.
    Respir Med; 2017 Feb 22; 123():8-17. PubMed ID: 28137501
    [Abstract] [Full Text] [Related]

  • 35. Early and sustained symptom improvement with umeclidinium/vilanterol versus monotherapy in COPD: a post hoc analysis of the EMAX randomised controlled trial.
    Kerwin EM, Boucot IH, Vogelmeier CF, Maltais F, Naya IP, Tombs L, Jones PW, Lipson DA, Keeley T, Bjermer L.
    Ther Adv Respir Dis; 2020 Feb 22; 14():1753466620926949. PubMed ID: 32462979
    [No Abstract] [Full Text] [Related]

  • 36. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD.
    Kempsford R, Norris V, Siederer S.
    Pulm Pharmacol Ther; 2013 Apr 22; 26(2):256-64. PubMed ID: 23232038
    [Abstract] [Full Text] [Related]

  • 37. Concentration-QT analysis of the randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
    Mehta R, Green M, Patel B, Wagg J.
    J Pharmacokinet Pharmacodyn; 2016 Apr 22; 43(2):153-64. PubMed ID: 26739997
    [Abstract] [Full Text] [Related]

  • 38. Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study.
    Mehta R, Kelleher D, Preece A, Hughes S, Crater G.
    Int J Chron Obstruct Pulmon Dis; 2013 Apr 22; 8():159-67. PubMed ID: 23569370
    [Abstract] [Full Text] [Related]

  • 39. Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life.
    Tabberer M, Lomas DA, Birk R, Brealey N, Zhu CQ, Pascoe S, Locantore N, Lipson DA.
    Adv Ther; 2018 Jan 22; 35(1):56-71. PubMed ID: 29313286
    [Abstract] [Full Text] [Related]

  • 40. Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD.
    Albertson TE, Bowman WS, Harper RW, Godbout RM, Murin S.
    Int J Chron Obstruct Pulmon Dis; 2019 Jan 22; 14():1251-1265. PubMed ID: 31239659
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.